Amgen's Patent Not Used In Neulasta Biosimilar, Mylan Says
Mylan Inc.'s proposed Neulasta biosimilar doesn't use the salt pairs covered in a patent Amgen Inc. is accusing it of infringing, Mylan told a Pennsylvania federal court Friday, hoping to get...To view the full article, register now.
Already a subscriber? Click here to view full article